Acelyrin, Inc. Board of Directors

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

Ms. Kelly Chow

Ms. Kelly Chow

Chief People Officer

Dr. Shephard Mpofu M.D.

Dr. Shephard Mpofu M.D.

Chief Medical Officer

Ms. Patricia A. Turney

Ms. Patricia A. Turney

Chief Technical Operations Officer

Mr. Tyler Marciniak

Mr. Tyler Marciniak

Head of Investor Relations & Communications

Mr. Kenneth A. Lock

Mr. Kenneth A. Lock

Chief Commercial Officer

Ms. Suzy Buckhalter CPA

Ms. Suzy Buckhalter CPA

Senior Director of Finance & Accounting

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.